ArticleJournal of labelled compounds & radiopharmaceuticals2009
In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.
Article in Journal of labelled compounds & radiopharmaceuticals, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Evaluation of [Molecular pharmaceutics · 2023Article
- Evaluation ofDiagnostics (Basel, Switzerland) · 2022Article
- Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides.Biomolecules · 2020Article
- Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.Oncotarget · 2017Article
- High-Throughput Approaches to the Development of Molecular Imaging Agents.Molecular imaging and biology · 2017Review
- Tumor-targeting peptides from combinatorial libraries.Advanced drug delivery reviews · 2017Review
- Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells.International journal of nanomedicine · 2017Article
- Multiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2.International journal of peptide research and therapeutics · 2015Article
- In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.Molecular imaging and biology · 2014Article
- Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.Molecular imaging and biology · 2014Article
- Identification of a Peptide fromJournal of molecular biomarkers & diagnosis · 2014Article
- Combinatorial peptide libraries: mining for cell-binding peptides.Chemical reviews · 2014Review
- In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.American journal of nuclear medicine and molecular imaging · 2014Article
- Article
- Identification of a LNCaP-specific binding peptide using phage display.Pharmaceutical research · 2011Article
- Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Aberrant expression of ErbB-2, a member of the epidermal growth factor family of receptors, has been implicated in the formation of various malignancies including ovarian cancer. The objective of this study was to determine if the bacteriophage (phage) display-selected ErbB-2 targeting peptide, KCCYSL, once radiolabeled with (111)In would serve as a tumor targeting and Single Photon Emission Computed Tomography (SPECT/CT) imaging agent in a mouse model of human ovarian carcinoma expressing ErbB-2. The KCCYSL peptide was synthesized with a chelator 1,4,7,10-tetra-azacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), and a Gly-Ser-Gly (GSG) spacer between DOTA and amino terminus of the peptide and radiolabeled with (111)InC1(3). In vitro cell binding studies indicated that (111)In-DOTA-GSG-KCCYSL bound to cultured ovcar-3 carcinoma cells. Biodistribution studies in scid mice bearing human ovcar-3 tumor xenografts revealed a tumor uptake of 0.50 ± 0.05 percent injected dose per gram (%ID/g) at 1 h, and 0.39 ± 0.1 %ID/g at 2 h. Blocking studies with non-radiolabeled counterpart indicated a partial inhibition (41%) (P = 0.04) in tumor uptake of (111)In-DOTA-GSG-KCCYSL. In vivo tumor uptake of (111)In-DOTA-GSG-KCCYSL was clearly evident through SPECT/CT images after 2 h post injection. These studies suggest the potential of this peptide as a radiopharmaceutical for imaging of ErbB-2-expressing ovarian tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.